Advertisement


Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

ESMO Congress 2022

Advertisement

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The GEMPAX study is a phase III randomized trial comparing in patients with metastatic pancreatic ductal adenocarcinoma second-line therapy with gemcitabine and paclitaxel versus gemcitabine alone. The primary endpoint of this study was overhaul survival. Patients included were having metastatic pancreatic ductal adenocarcinoma, they were having experienced disease progression of failure after FOLFIRINOX, and maintaining a good ECOG performance status. They were randomized with a 2:1 ratio between GEMPAX, the weekly combination of gemcitabine and paclitaxel, 3 weeks over 4 versus gemcitabine alone. They stopped treatment at disease progression or toxicity. There were four stratification factors, ECOG PS, CA19-9 at baseline, first-line PFS, and neutrophil to lymphocyte ratio. The main results of this study is that we didn't observe any significant benefit in overall survival with the addition of paclitaxel to gemcitabine versus gemcitabine alone in this setting. But this is the first prospective phase III trial evaluating second-line therapy after FOLFIRINOX and we observe a good improvement of progression-free survival, a significant one, and also a significant increase in overall response rate, which is highly clinically relevant in this poor prognosis disease. Furthermore, we observed more treatment discontinuation in the GEMPAX arm and also imbalance in third-line therapies that could explain the absence of overall survival benefit. Then, we think that gemcitabine plus paclitaxel may be the standard second-line therapy after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma patients. A substantial proportion of patients in this study received third-line therapies, reflecting the eye medical need, and also the requiring further clinical trials for this pathology.

Related Videos

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Recent Phase III Data on Cabozantinib, Nivolumab, and Ipilimumab From the COSMIC-313 Trial

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss phase III findings showing that cabozantinib in combination with nivolumab and ipilimumab reduced the risk of disease progression or death compared with the combination of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma of IMDC (the International Metastatic RCC Database Consortium) intermediate or poor risk. However, the combination of cabozantinib, nivolumab, and ipilimumab vs nivolumab plus ipilimumab did not demonstrate an overall survival benefit to patients (Abstract LBA8).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer (NSCLC); and the ORIENT-31 trial, which compared sintilimab with or without IBI305 (a bevacizumab biosimilar) plus chemotherapy in patients with EGFR-mutated nonsquamous NSCLC who experienced disease progression on EGFR tyrosine kinase inhibitors.

Skin Cancer
Immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).

Colorectal Cancer

Marinde J.G. Bond, PhD Candidate, on Colorectal Liver Metastases: FOLFOX/FOLFIRI, Bevacizumab, and Panitumumab

Marinde J.G. Bond, PhD Candidate, of the University Medical Center, Utrecht, discusses phase III findings from the CAIRO5 study of the Dutch Colorectal Cancer Group, the first such trial in defined subgroups of patients with initially unresectable colorectal cancer liver metastases and left-sided and RAS/BRAF V600E wild-type tumor. The study compared FOLFOX/FOLFIRI plus either bevacizumab or panitumumab (Abstract LBA21).

 

Prostate Cancer

Rahul Aggarwal, MD, on Prostate Cancer: Phase III Data on Apalutamide and Androgen Deprivation in Relapsed Disease

Rahul Aggarwal, MD, of the University of California, San Francisco, discusses recent data from the PRESTO study, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with biochemically recurrent prostate cancer. These results provide support for the intensification of ADT in this setting. (Abstract LBA63).

Advertisement

Advertisement




Advertisement